Russian experience with perampanel in routine clinical practice

Nevrologiâ, Nejropsihiatriâ, Psihosomatika

E. N. Paramonova¹  O. I. Miguskina²  I. V. Ponomareva³  D. V. Dmitrenko⁴  P. N. Vlasov⁵  I. A. Zhidkova⁵  V. A. Karlov⁵  I. V. Volkov⁶  A. Yu. Karas⁷  O. V. Belyaev⁸  T. V. Kazennykh⁹  A. V. Chervyakov^1,10  A. V. Moskvicheva^1,11 

[1] Center for Epilepsy, Paroxysmal States, and Sleep Disorders, Novosibirsk, Russia;City Clinical Hospital Eleven, Novosibirsk, Russia;City Clinical Hospital Four, Chelyabinsk, Russia;Department of Medical Genetics and Clinical Neurophysiology, Institute of Postgraduate Education, Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia, Krasnoyarsk, Russia;Department of Nervous System Diseases, Faculty of General Medicine, A.I. Evdokimov Moscow State University of Medicine and Dentistry,Ministry of Health of Russia, Moscow, Russia;Epileptology Center, Sibneiromed Multidisciplinary Clinic, Novosibirsk, Russia;Medical Center for Neurology and Epilepsy Diagnosis and Treatment, Saratov, Russia;Medical Center for Neurology and Epilepsy Diagnosis and Treatment, Volgograd, Russia;Mental Health Research Institute, Tomsk, Russia;Neurology Research Center, Moscow;Repiblican Children's Clinical Hospital, Ministry of Health and Social Development of Chuvashia, Cheboksary, Russia;

关键词: perampanel;    drug-resistant focal/partial epilepsy;    efficacy;    tolerability;    safety;    adverse events;    side effects;   

DOI  :  10.14412/2074-2711-2016-1S-11-17

来源: DOAJ

【 摘 要 】

Objective: to generalize the Russian experience with perampanel (PER) in routine clinical practice; to do this, the results of its use as an adjuvant partial epilepsy medication were retrospectively assessed. The study is still in progress now; therefore, the paper gives its preliminary results. Patients and methods. The investigation included 52 patients with drug-resistant partial epilepsy. Their mean age was 28.92±14.02 years (asmall number of the patients had not attained the age of 12 years); the proportion of men was 56%; the disease duration was over 10 years (69.2%); symptomatic epilepsy was in 76.9% with an epileptic focus being in the frontal (46.2%) and temporal (44.2%) regions. PER was prescribed to the majority (71.2%) of patients after three previous therapy lines. The baseline monthly rates of all types of seizures were 127.29±82.29; those of generalized seizures were 6.72±1.90.Results and discussion. After addition of PER to therapy just within the first month, there was a significant reduction in the frequency of all types of seizures to 52.06±29.26 per month (Sign test; p = 0.00001) and in that of secondary generalized seizures to 3.71±1.71 (Sign test; p=0.00001). The duration of PER administration was more than 6 months in the overwhelming majority of cases. In 58% of the patients, the frequency of seizures decreased by more than 50% (respondents). The lack of all types of seizures was noted in 8%; that of only secondary generalized seizures was in 31%. Adverse  events were observed in 30.1% of the patients (aggression in 11.5% and somnolence in 9.6%; others were seen more rarely). The dose of PER was decreased because of side effects in 7 (13.5%) patients; the drug was discontinued in 4 (7.7%). The mean dose of PER for adults was as high as 6 mg.

【 授权许可】

Unknown